Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Rating Upgraded by Wall Street Zen

Crinetics Pharmaceuticals (NASDAQ:CRNX) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Several other brokerages have also recently commented on CRNX. The Goldman Sachs Group upgraded shares of Crinetics Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $67.00 target price for the company in a report on Monday, January 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Crinetics Pharmaceuticals in a research report on Wednesday, January 21st. Citizens Jmp decreased their price objective on shares of Crinetics Pharmaceuticals from $108.00 to $105.00 and set a “market outperform” rating for the company in a research note on Thursday, January 8th. Morgan Stanley boosted their target price on shares of Crinetics Pharmaceuticals from $77.00 to $80.00 and gave the company an “overweight” rating in a research note on Tuesday, January 6th. Finally, Lifesci Capital upgraded Crinetics Pharmaceuticals to a “strong-buy” rating in a report on Friday, February 13th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $75.78.

Crinetics Pharmaceuticals Stock Down 6.0%

Shares of NASDAQ CRNX opened at $41.10 on Friday. The stock’s fifty day simple moving average is $48.83 and its 200 day simple moving average is $43.11. The stock has a market capitalization of $4.20 billion, a price-to-earnings ratio of -8.32 and a beta of 0.19. Crinetics Pharmaceuticals has a 52-week low of $24.10 and a 52-week high of $57.99.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last announced its earnings results on Thursday, February 26th. The company reported ($1.29) EPS for the quarter, beating the consensus estimate of ($1.37) by $0.08. The business had revenue of $3.89 million during the quarter, compared to the consensus estimate of $4.32 million. Crinetics Pharmaceuticals had a negative return on equity of 39.91% and a negative net margin of 6,046.22%.Crinetics Pharmaceuticals’s revenue was up NaN% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.88) earnings per share. As a group, analysts anticipate that Crinetics Pharmaceuticals will post -3.73 earnings per share for the current year.

Insider Activity

In related news, insider Isabel Kalofonos sold 2,500 shares of Crinetics Pharmaceuticals stock in a transaction on Monday, January 5th. The stock was sold at an average price of $55.00, for a total transaction of $137,500.00. Following the completion of the sale, the insider owned 834 shares of the company’s stock, valued at approximately $45,870. This trade represents a 74.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.60% of the company’s stock.

Institutional Investors Weigh In On Crinetics Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP lifted its holdings in shares of Crinetics Pharmaceuticals by 44.3% during the 3rd quarter. Wellington Management Group LLP now owns 8,381,991 shares of the company’s stock valued at $349,110,000 after buying an additional 2,574,683 shares during the last quarter. Baker BROS. Advisors LP raised its position in Crinetics Pharmaceuticals by 488.9% during the fourth quarter. Baker BROS. Advisors LP now owns 1,648,869 shares of the company’s stock valued at $76,755,000 after acquiring an additional 1,368,869 shares in the last quarter. Farallon Capital Management LLC lifted its stake in Crinetics Pharmaceuticals by 20.2% in the fourth quarter. Farallon Capital Management LLC now owns 6,933,098 shares of the company’s stock valued at $322,736,000 after acquiring an additional 1,163,000 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Crinetics Pharmaceuticals by 279.2% in the third quarter. JPMorgan Chase & Co. now owns 1,258,722 shares of the company’s stock valued at $52,426,000 after acquiring an additional 926,765 shares during the last quarter. Finally, GW&K Investment Management LLC grew its position in Crinetics Pharmaceuticals by 73.6% in the fourth quarter. GW&K Investment Management LLC now owns 1,476,325 shares of the company’s stock worth $68,723,000 after acquiring an additional 625,779 shares in the last quarter. 98.51% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Crinetics Pharmaceuticals

Here are the key news stories impacting Crinetics Pharmaceuticals this week:

• Positive Sentiment: Q4 EPS beat consensus: Crinetics reported a narrower-than-expected loss (GAAP EPS of -$1.29 vs. the -$1.37 consensus), which can be viewed as a modest positive on execution vs. expectations. MarketBeat Earnings Summary
• Positive Sentiment: Management emphasized product launch momentum and provided a business update on the earnings call, signaling commercial progress that could support future revenue growth if sustained. Earnings Call Highlights
• Neutral Sentiment: Full earnings materials and transcripts published — investors can review the call transcript and slides for detail on guidance, launch metrics and timing. Seeking Alpha Transcript Slide Deck
• Neutral Sentiment: Reported short-interest data in system appears inconclusive/zeroed out for February (no actionable increase). This entry likely has no material impact until validated by official exchanges.
• Negative Sentiment: Revenue missed Street expectations (reported ~$3.9M vs. ~$4.3M consensus) and the company’s quarterly loss widened year-over-year — a revenue shortfall and rising losses can pressure sentiment, especially for a company transitioning to commercial sales. Zacks Earnings Note
• Negative Sentiment: Analysts and commentators flagged a new shelf/ESOP registration alongside discussion of product launch momentum — while the shelf can enable capital raises and fund commercialization, it also raises near-term dilution concerns that can hurt the share price. Yahoo Analysis

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases. The company’s proprietary platform leverages insights into hormone receptor signaling to design small-molecule candidates that address conditions driven by dysregulated hormone activity. Crinetics’ research efforts center on targeting somatostatin, vasopressin and other GPCR-mediated pathways with orally bioavailable molecules intended to improve patient convenience and adherence.

The company’s lead product candidate, paltusotine (formerly CRN04777), is a selective, non-peptide somatostatin receptor type 2 agonist being evaluated for the treatment of acromegaly and carcinoid syndrome diarrhea.